Prosthetic Heart Valve Market: as Edwards secures the first-ever FDA approval for TAVR in asymptomatic patients and CMS moves to remove coverage restrictions that have long capped the addressable surgical candidate pool, transcatheter valve therapy is positioned for its largest single eligibility expansion since the original low-risk approvals, so regulatory and reimbursement policy is now a more immediate growth lever than incremental device engineering alone.

The global prosthetic heart valve market size was USD 9.84 Billion in 2025 and is expected to register a revenue CAGR of 7.1% during the forecast period.Market revenue growth is driven by factors such as transcatheter aortic valve replacement expansion into lower-risk and asymptomatic patient populations, commercial development of transcatheter mitral and tricuspid valve therapy, and evolving reimbursement policy removing longstanding coverage restrictions on transcatheter valve procedures.The first driving factor is transcatheter aortic valve replacement expansion into lower-risk and, most recently, asymptomatic patient populations, substantially widening the addressable surgical candidate pool beyond the original high-risk approval cohorts.The second driving factor is commercial development of transcatheter mitral and tricuspid valve therapy, extending structural heart intervention beyond aortic disease into the two other major heart valve categories.The third driving factor is evolving CMS reimbursement policy, including proposed removal of coverage restrictions that have historically limited transcatheter procedure volume growth.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single regulatory or reimbursement policy change widens the addressable patient population for every manufacturer's approved valve platform simultaneously, converting one policy decision into procedure volume growth across the entire competitive field rather than benefiting only the manufacturer that sought the change.Once CMS or the FDA expands the approved patient population for transcatheter valve therapy, every manufacturer with an already-approved valve platform immediately gains access to that newly eligible patient population without needing a separate approval of their own, so procedure volume compounds across the entire competitive field the moment the policy change takes effect.As a result, demand and revenue share are concentrating around manufacturers whose valve platforms already hold broad-population approvals ahead of policy change, that hold the deepest clinical evidence supporting expanded indications, and the forecast tilts toward these approval-ready incumbents rather than manufacturers still pursuing initial regulatory clearance.For instance, in April 2025, Edwards Lifesciences received the first-ever FDA approval for TAVR therapy in asymptomatic severe aortic stenosis patients, based on the EARLY TAVR trial demonstrating superior outcomes compared to guideline-recommended watchful waiting, immediately expanding the eligible patient population for Edwards' SAPIEN 3 platform beyond the symptomatic patients who previously defined the addressable market.These are some of the key factors driving revenue growth of the market.

Because transcatheter valve procedures carry residual risk of paravalvular leak and long-term structural valve deterioration, particularly in younger patients receiving valves earlier in their disease course, this creates durability uncertainty that tempers unrestricted expansion into the youngest, lowest-risk patient populations.

Hospital catheterisation laboratory and hybrid operating room capacity constraints are a second constraint, as expanding eligible patient populations require proportional growth in procedural capacity that hospital capital investment cycles cannot always match immediately.

Pacemaker implantation risk following transcatheter aortic valve replacement is a third constraint, as conduction system injury during valve deployment continues to require permanent pacemaker implantation in a meaningful minority of patients across most currently approved valve platforms.

These factors substantially limit prosthetic heart valve market growth over the forecast period.

The clearest driver of demand is the regulatory and reimbursement expansion of TAVR eligibility into the substantially larger asymptomatic severe aortic stenosis population that has historically been managed with watchful waiting rather than intervention. A transcatheter valve platform only captures the full addressable asymptomatic patient population if both FDA approval and CMS reimbursement coverage exist simultaneously, since regulatory clearance alone does not guarantee hospital-level procedure volume without a corresponding payment pathway. In April 2025, Edwards Lifesciences received FDA approval for its SAPIEN 3 platform in asymptomatic severe aortic stenosis patients based on the EARLY TAVR trial, which demonstrated that asymptomatic patients randomized to TAVR experienced superior outcomes compared to guideline-recommended clinical surveillance, with untreated symptomatic severe AS carrying up to a 1-in-10 five-week mortality risk once symptoms emerge. CMS proposed an update to its National Coverage Determination, initiated after accepting a request from Edwards Lifesciences, that would extend coverage to asymptomatic TAVR procedures, remove the coverage-with-evidence-development requirement for symptomatic procedures, and eliminate hospital volume requirements, with completion targeted for September 13, 2026. The effect on the market is that the addressable TAVR patient population is positioned for its largest single expansion since the original extension into low-risk patients, benefiting every manufacturer with an approved valve platform simultaneously once the coverage determination is finalised. These are some of the key factors driving revenue growth of the market.

The second driver is the maturation of transcatheter valve technology beyond aortic stenosis into the mitral and tricuspid valve categories and into aortic disease presentations that earlier-generation valves could not adequately treat. A transcatheter valve platform only addresses aortic regurgitation, as distinct from aortic stenosis, if it is specifically engineered to anchor securely in the absence of the calcium deposits that conventional TAVR valves rely on for stable positioning, and JenaValve's Trilogy system's locator technology was purpose-built to solve exactly that anchoring challenge. In March 2026, the FDA approved JenaValve's Trilogy TAVR system for aortic regurgitation based on positive data from the ALIGN-AR trial, representing the first answer to what the cardiology community had long struggled with: safely and effectively treating patients with severe aortic regurgitation using a transcatheter device. Boston Scientific's option agreement with MiRus, providing a pathway to full ownership of MiRus's investigational SIEGEL balloon-expandable TAVR system and an exclusive option on MiRus's mitral and tricuspid replacement valve assets, reflects the broader industry pattern of established manufacturers re-entering or expanding structural heart valve categories through targeted acquisition rather than solely internal development. The effect on the market is that the addressable structural heart disease population is expanding beyond aortic stenosis into aortic regurgitation, mitral disease, and tricuspid disease, categories that previously had limited or no transcatheter treatment options. These are some of the key factors driving revenue growth of the market.

“Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis may die within five weeks, and the EARLY TAVR trial demonstrated that treating patients before symptoms even emerge produces superior outcomes compared to guideline-recommended watchful waiting.”

However, the prosthetic heart valve market faces severe adoption constraints from paravalvular leak and structural valve deterioration risk, hospital catheterisation laboratory capacity constraints, and pacemaker implantation risk following TAVR.

Because transcatheter valve procedures carry residual risk of paravalvular leak and long-term structural valve deterioration, particularly relevant as indications expand into younger, lower-risk, and now asymptomatic patients who will live with their implanted valve for a longer duration, this creates durability uncertainty that tempers unrestricted expansion into the youngest patient populations.

Hospital catheterisation laboratory and hybrid operating room capacity constraints compound this, as expanding eligible patient populations following regulatory and reimbursement policy changes require proportional growth in procedural capacity that hospital capital investment cycles cannot always match immediately, potentially creating access bottlenecks even where clinical and payment eligibility now exist.

Pacemaker implantation risk following transcatheter aortic valve replacement is the third constraint, as conduction system injury during valve deployment continues to require permanent pacemaker implantation in a meaningful minority of patients, with implantation rates varying by valve platform and creating an ongoing procedural complication consideration even as overall TAVR safety profiles continue to improve.

These factors substantially limit prosthetic heart valve market growth over the forecast period.

Based on type, the global prosthetic heart valve market is segmented into transcatheter aortic, transcatheter mitral, transcatheter tricuspid, surgical bioprosthetic, and surgical mechanical valves. Transcatheter aortic valves hold the largest revenue share, because TAVR has become the dominant treatment modality for aortic stenosis across the full spectrum of surgical risk following successive indication expansions into intermediate, low-risk, and now asymptomatic patient populations. Transcatheter tricuspid valves are expected to register the fastest revenue growth rate over the forecast period, driven by commercial development addressing a structural heart disease category that has historically lacked effective transcatheter treatment options at manufacturers including Edwards Lifesciences and Abbott.

Based on implantation procedure, the global prosthetic heart valve market is segmented into transcatheter, minimally invasive surgical, and open heart surgical routes. Transcatheter procedures hold a significantly large revenue share, reflecting the structural shift away from open heart sternotomy toward catheter-based delivery across virtually every valve category and patient risk profile. Minimally invasive surgical procedures are expected to register the fastest revenue growth rate among non-transcatheter routes, driven by surgical valve innovation for patients whose anatomy remains better suited to surgical rather than transcatheter approaches.

Based on regional analysis, the prosthetic heart valve market in North America accounted for largest revenue share in 2025. The United States leads because CMS reimbursement policy directly shapes TAVR procedure volume nationally, and because the country hosts the headquarters of Edwards Lifesciences, Medtronic's US operations, and Abbott, the three largest global prosthetic heart valve manufacturers. The pending CMS National Coverage Determination update, targeted for completion by September 13, 2026, reflects the concentration of transcatheter valve reimbursement policy decision-making at the US federal level with direct implications for procedure volume nationwide. The concentration of leading structural heart manufacturers in the United States also means new valve indications and technologies are often approved and piloted domestically before being extended to other regions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and Italy represent the four largest national markets, with Edwards Lifesciences and Medtronic together controlling an estimated 80% share of the European TAVR market. European structural heart procedure volume continues to expand alongside established national health service reimbursement frameworks, but national procurement cycle timing creates more measured indication rollout pacing relative to the United States. The result is steady rather than rapid growth, shaped more by national procurement cycle timing than by underlying demographic demand.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period, driven by China, Japan, and India's expanding structural heart programme infrastructure and rising aortic stenosis diagnosis rates. China's rapidly expanding hospital network and Japan's aging population sustaining high per-capita structural heart disease prevalence are the region's two largest growth contributors. This leaves more room for growth than in the more mature North American and European prosthetic heart valve markets, where manufacturer-institution relationships are already largely established.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets, with structural heart programme access concentrated at academic medical centres in São Paulo and Mexico City. Iran-US sanctions continue to disrupt freight and import costs for the specialised bovine and porcine pericardial tissue, nitinol frame components, and delivery catheter materials that Latin American prosthetic heart valve distributors depend on, with cargo rerouting around the Strait of Hormuz corridor raising landed component costs and slowing valve distribution beyond the region's main academic centres through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary GCC commercial markets, with the Saudi Vision 2030 healthcare investment programme driving new structural heart programme development. The UAE is the most established market on the continent for transcatheter valve procedure capability, while the Gulf states more broadly are still building specialist structural heart infrastructure largely from scratch.